Durvalumab Inhibitor

Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04nM, respectively.

Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment,of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.
Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment,of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.
Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.
Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.

Small volumes of Durvalumab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5753057 is an inhibitor targeting Durvalumab.